The Foot & Ankle Consolidation Trend Continues
On May 4, CONMED Corporation (NYSE: CNMD) announced a definitive agreement to acquire privately-held In2Bones Global, Inc. for cash consideration of $145 million at closing and up to an additional $110 million in growth-based earnout payments over a four-year period.
In2Bone, led by foot and ankle veteran Alan Taylor, had 2021 revenue of $36.8 million with sustained double-digit growth. While CONMED is a large company, including 3,500 employees, it has a small footprint in foot and ankle, making this a partnership an upside on both sides.
Recent Posts
See AllOssiumHealth processing bone marrow from organ donors at scale. They process and cryopreserve while ensuring the bone marrow is phenotypically and functionally equivalent to cells from living donors.
by Vince Vacketta, DPM Weight bearing CT (WBCT) has proven to be a valuable tool for foot and ankle surgeons. One study looking at the WBCT experience of an orthopedic practice found revenue neutral w
